inclusion criteria: 1. written informed consent approved by the investigator's institutional review board (irb)/independent ethics committee (iec), prior to the performance of any trial activities. 2. age 18 years or older. 3. patients with positive rt-pcr or igm/igg blood test for sars-cov-2 prior to the inclusion in the study. 4. patients that have pneumonia associated to sars-cov-s infection prior to randomization. 5. patients having respiratory dysfunction after sars-cov-2 infection and abnormal ct chest imaging. 6. patients previously under high flow nasal cannula or non-invasive ventilation, or supplementary oxygen, during hospitalization for covid-19. 7. increased egf level (more than 200 picogram/ml). 8. negative serum pregnancy test at screening for women of childbearing potential. 9. highly effective contraception for both male and female subjects throughout the study and for at least 3 months after last imp treatment administration if the risk of conception exists.

inclusion criteria: 1. written informed consent approved by the investigator's institutional review board (irb)/independent ethics committee (iec), prior to the performance of any trial activities. 2. age 18 years or older. 3. patients with positive rt-pcr or igm/igg blood test for sars-cov-2 prior to the inclusion in the study. 4. patients that have pneumonia associated to sars-cov-s infection prior to randomization. 5. patients having respiratory dysfunction after sars-cov-2 infection and abnormal ct chest imaging. 6. patients previously under high flow nasal cannula or non-invasive ventilation, or supplementary oxygen, during hospitalization for covid-19. 7. increased egf level (more than 200 picogram/ml). 8. negative serum pregnancy test at screening for women of childbearing potential. 9. highly effective contraception for both male and female subjects throughout the study and for at least 3 months after last imp treatment administration if the risk of conception exists.

inclusion criteria: written informed consent approved by the investigator's institutional review board (irb)/independent ethics committee (iec), prior to the performance of any trial activities. age 18 years or older. patients with positive rt-pcr or igm/igg blood test for sars-cov-2 prior to the inclusion in the study. patients that have pneumonia associated to sars-cov-s infection prior to randomization. patients having respiratory dysfunction after sars-cov-2 infection and abnormal ct chest imaging. patients previously under high flow nasal cannula or non-invasive ventilation, or supplementary oxygen, during hospitalization for covid-19. increased egf level (more than 200 picogram/ml). negative serum pregnancy test at screening for women of childbearing potential. highly effective contraception for both male and female subjects throughout the study and for at least 3 months after last imp treatment administration if the risk of conception exists.

inclusion criteria: written informed consent approved by the investigator's institutional review board (irb)/independent ethics committee (iec), prior to the performance of any trial activities. age 18 years or older. patients with positive rt-pcr or igm/igg blood test for sars-cov-2 prior to the inclusion in the study. patients that have pneumonia associated to sars-cov-s infection prior to randomization. patients having respiratory dysfunction after sars-cov-2 infection and abnormal ct chest imaging. patients previously under high flow nasal cannula or non-invasive ventilation, or supplementary oxygen, during hospitalization for covid-19. increased egf level (more than 200 picogram/ml). negative serum pregnancy test at screening for women of childbearing potential. highly effective contraception for both male and female subjects throughout the study and for at least 3 months after last imp treatment administration if the risk of conception exists.

inclusion criteria: 1. written informed consent approved by the investigator's institutional review board (irb)/independent ethics committee (iec), prior to the performance of any trial activities. 2. age 18 years or older. 3. patients with positive rt-pcr or igm/igg blood test for sars-cov-2 prior to the inclusion in the study. 4. patients that have pneumonia associated to sars-cov-s infection prior to randomization. 5. patients having respiratory dysfunction after sars-cov-2 infection and abnormal ct chest imaging. 6. patients previously under high flow nasal cannula or non-invasive ventilation, or supplementary oxygen, during hospitalization for covid-19. 7. increased egf level (more than 200 picogram/ml). 8. negative serum pregnancy test at screening for women of childbearing potential. 9. highly effective contraception for both male and female subjects throughout the study and for at least 3 months after last imp treatment administration if the risk of conception exists.

inclusion criteria: 1. written informed consent approved by the investigator's institutional review board (irb)/independent ethics committee (iec), prior to the performance of any trial activities. 2. age 18 years or older. 3. patients with positive rt-pcr or igm/igg blood test for sars-cov-2 prior to the inclusion in the study. 4. patients that have pneumonia associated to sars-cov-s infection prior to randomization. 5. patients having respiratory dysfunction after sars-cov-2 infection and abnormal ct chest imaging. 6. patients previously under high flow nasal cannula or non-invasive ventilation, or supplementary oxygen, during hospitalization for covid-19. 7. increased egf level (more than 200 picogram/ml). 8. negative serum pregnancy test at screening for women of childbearing potential. 9. highly effective contraception for both male and female subjects throughout the study and for at least 3 months after last imp treatment administration if the risk of conception exists.